Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC

BACKGROUND: Alectinib is approved for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring ALK rearrangements. Although generally well tolerated, alectinib can cause serious or life-threatening side effects. CASE PRESENTATION: Here, we report a case of a patient with NSCLC with an...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Ling, Xiao, Kui, Cui, Jian, Ye, Xiang-Hua, Zhang, Yong-Chang, Mao, Li, Selvaggi, Giovanni, Yen, Jennifer, Stebbing, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164872/
https://www.ncbi.nlm.nih.gov/pubmed/34079286
http://dx.doi.org/10.2147/OTT.S310756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164872/
https://www.ncbi.nlm.nih.gov/pubmed/34079286
http://dx.doi.org/10.2147/OTT.S310756

Ejemplares similares